Get the Stockscreener App
8.07
8.83%
0.655
After Hours:
8.07
Immunitybio Inc stock is traded at $8.07, with a volume of 28.87M.
It is up +8.83% in the last 24 hours and down -15.41% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.415
Open:
$7.75
24h Volume:
28.87M
Relative Volume:
0.80
Market Cap:
$8.30B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-20.70
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-5.72%
1M Performance:
-15.41%
6M Performance:
+228.05%
1Y Performance:
+194.53%
1-Day Range:
$7.45
$8.35
1-Week Range:
$6.54
$9.54
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.07 | 7.62B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (NASDAQ:IBRX) Trading Up 8.9%Still a Buy? - MarketBeat
FDA Objects to Claims by Soon-Shiong on Cancer Drug - newser.com
FDA Issues Warning Letter to ImmunityBio | PharmExec - Pharmaceutical Executive
Why the FDA flagged ImmunityBio’s ‘false and misleading’ claims in podcast, TV spot - Medical Marketing and Media
ImmunityBio’s Global Expansion Raises Stock Speculation - timothysykes.com
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report? - Yahoo Finance Australia
ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China - Yahoo Finance
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement - Pharmaceutical Executive
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims - TradingView
IBRX stock still a buy after worst day in over a year? Why this analyst is shrugging off FDA warning letter - MSN
FDA warns manufacturer that billionaire's claims about cancer drug Anktiva are misleading - CBS News
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX - The National Law Review
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
Kaplan Fox Investigating ImmunityBio for Potential Securities Violations - National Today
Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations - The National Law Review
FDA slams Soon-Shiong and ImmunityBio for making 'false and misleading' claims about a drug - statnews.com
FDA Issues Warning Letter to ImmunityBio Over 'False and Misleading' Claims for Bladder Cancer Drug Anktiva - drugscontrol.org
Drugmaker’s stock tumbles 20% after FDA issues formal warning to executives - HealthExec
Biopharma bites: ImmunityBio's 'misleading' ad, UCB's manufacturing hub, plus Aardvark's obesity pause - FirstWord Pharma
ImmunityBio (NASDAQ:IBRX) Trading Down 21.1%Time to Sell? - MarketBeat
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - KIRO 7 News Seattle
Immunitybio Inc.Bio, News, Photos - Washington Times
Is ImmunityBio (IBRX) Still Attractive After A 365% Year To Date Surge - simplywall.st
ImmunityBio Gains on Anktiva Approval in Macau, First in Asia | 2026News and Statistics - IndexBox
ImmunityBio Stock Falls on FDA Warning. No, Its Drug Can’t ‘Treat All Cancers.’ - Barron's
FDA Flags Misleading Claims on Cancer Drug Made by Billionaire Owner of ImmunityBio - MedPage Today
ImmunityBio stock price crash: buy the dip or sell the rip? - Invezz
Biotech Billionaire Gets FDA Warning Over Cancer Drug Claims - Fine Day 102.3
BTIG reiterates Immunitybio stock Buy rating after FDA warning By Investing.com - Investing.com Canada
Why ImmunityBio Stock Is Down More Than 20% Today - AOL.com
BTIG reiterates Immunitybio stock Buy rating after FDA warning - Investing.com
“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26% - TipRanks
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode - Fierce Pharma
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy - Yahoo Finance
Promising Biotech Stocks Worth WatchingMarch 24th - MarketBeat
US FDA sends warning letter to ImmunityBio for "false or misleading" TV ad and podcast on Anktiva - marketscreener.com
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad - TradingView
ImmunityBio initiates review after receiving FDA letter on Anktiva promotional materials - marketscreener.com
ImmunityBio Plunges After Getting FDA Warning on Cancer Drug Anktiva - Bloomberg.com
ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials - TradingView
FDA warns ImmunityBio over misleading podcast with Patrick Soon-Shiong - Endpoints News
Why ImmunityBio’s cancer drug claims alarmed the FDA - Rolling Out
ImmunityBio Faces Market Impact After Large Share Sale - StocksToTrade
ImmunityBio (IBRX) Shares Plunge 21% Following FDA Warning Letter on Misleading Cancer Drug Marketing - Blockonomi
ImmunityBio shares plunge after FDA warning over misleading ads - Investing.com
ImmunityBio (IBRX) Stock Drops 21% After FDA Says Its Cancer Drug Ads Broke the Law - CoinCentral
ImmunityBio stock falls after FDA warning (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Plunges After Getting FDA Warning on Cancer Drug - Bloomberg.com
ImmunityBio stock tumbles after FDA warning on misleading ads - Investing.com
A Look At ImmunityBio (IBRX) Valuation After ANKTIVA’s Macau Approval And NCCN Guideline Expansion - Yahoo Finance
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):